Biogen (XSWX:BIIB) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIIB Biogen Inc XSWX:BIIB
69 GF Score
Price CHF173.46
GF Value CHF164.93
! 7 Warning Signs
View Full Analysis

What is Biogen Net Loan?

Net Loan only applies to banks and insurance companies.

XSWX:BIIB
69GF Score
Biogen Inc XSWX:BIIB
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biogen (XSWX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of CHF173.46 is trading 5.2% above its estimated GF Value™ of CHF164.93.

Key valuation signals for XSWX:BIIB:

  • Net Loan:
  • GF Value™: CHF164.93 vs. price of CHF173.46 (5.2% above fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
69GF Score

Get the complete analysis for XSWX:BIIB

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF173.46
Price
CHF164.93
GF Value